Original ArticlesRandomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer
Under a Creative Commons license
open archive
Key words:
Calcineurin inhibitor
Immunosuppression
kidney transplantation
nonmelanoma skin cancer
sirolimus
Abbreviations:
ANCOVA
analysis of covariance
BCC
basal cell carcinoma
CNI
calcineurin inhibitor
CORE
Clinical Operation Randomization Environment
GFR
glomerular filtration rate
mTOR
mammalian target of rapamycin
NMSC
nonmelanoma skin cancer
SCC
squamous cell carcinoma
Cited by (0)
- †
Current address: Royal Adelaide Hospital, Adelaide, Australia. ClinicalTrials.gov registry number: NCT00129961 Presented in part at the American Transplant Congress, Boston, MA, May 30–June 3, 2009, at the European Society of Transplantation, Paris, France, August 30–September 2, 2009, and at the American Society of Nephrology, San Diego, CA, USA, October 29–November 1, 2009.
Copyright © 2012 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.